Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Fiche publication
Date publication
juillet 2020
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOREL Christian
Tous les auteurs :
Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C, Rolfe PA, Gulley JL, Penel N
Lien Pubmed
Résumé
We report the clinical activity and safety of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β)RII receptor (a TGF-β 'trap') fused to a human IgG1 monoclonal antibody blocking programmed death-ligand 1 (PD-L1), in patients with heavily pretreated squamous cell carcinoma of the head and neck (SCCHN).
Mots clés
clinical trials as topic, head and neck neoplasms, immunotherapy
Référence
J Immunother Cancer. 2020 Jul;8(2):